[P4, a new substance for the treatment of Parkinson syndrome. Initial results of a clinical trial].
[P4, a new substance for the treatment of Parkinson syndrome. Initial results of a clinical trial].
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
In fourteen patients with a pronounced Parkinson syndrome of cerebral atherosclerotic or dostencephalitic genesis, good to very good success can be achieved with an average dosage of 3--4 tablets, three times a day (=45--60 mg) of the test substance, which is a bencilic acid ester preparation. The tremor, hypokinesis, and the psychic syndrome were particularly favourably affected. This success was also achieved in clinical pictures which had already lasted more than ten years.